{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:43:21Z","timestamp":1784598201196,"version":"3.55.0"},"reference-count":84,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12,1]]},"abstract":"<jats:p>Almost all current vaccines work by the induction of antibodies in serum or on the mucosa to block adherence of pathogens to epithelial cells or interfere with microbial invasion of the bloodstream. However, antibody levels usually decline after vaccination to undetectable amounts if further vaccination does not occur. Persistence of vaccine-induced antibodies usually goes well beyond the time when they should have decayed to undetectable levels because of ongoing \u201cnatural\u201d boosting or other immunologic mechanisms. The production of memory B and T cells is of clear importance, but the likelihood that a memory response will be fast enough in the absence of a protective circulating antibody level likely depends on the pace of pathogenesis of a specific organism. This concept is discussed with regard to Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis; hepatitis A and B; diphtheria, tetanus, and pertussis; polio, measles, mumps, rubella, and varicella; rotavirus; and human papilloma virus. With infectious diseases for which the pace of pathogenesis is less rapid, some individuals will contract infection before the memory response is fully activated and implemented. With infectious diseases for which the pace of pathogenesis is slow, immune memory should be sufficient to prevent disease.<\/jats:p>","DOI":"10.1542\/peds.2008-3645","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T02:44:08Z","timestamp":1259030648000},"page":"1633-1641","source":"Crossref","is-referenced-by-count":83,"title":["Booster Vaccinations: Can Immunologic Memory Outpace Disease Pathogenesis?"],"prefix":"10.1542","volume":"124","author":[{"given":"Michael E.","family":"Pichichero","sequence":"first","affiliation":[{"name":"Rochester General Research Institute, Rochester General Hospital, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,12,1]]},"reference":[{"key":"2021120905211791700_R1","doi-asserted-by":"crossref","unstructured":"Robbins JB, Schneerson R, Szu S. Perspective: hypothesis\u2014serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis.\u20081995;171(6):1387\u20131398","DOI":"10.1093\/infdis\/171.6.1387"},{"key":"2021120905211791700_R2","doi-asserted-by":"crossref","unstructured":"Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis.\u20082008;47(3):401\u2013408","DOI":"10.1086\/589862"},{"key":"2021120905211791700_R3","doi-asserted-by":"crossref","unstructured":"Zinkernagle RM, Hengartner H. Protective \u201cimmunity\u201d by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called \u201cimmunological memory.\u201d Immunol Rev. 2006;211:310\u2013319","DOI":"10.1111\/j.0105-2896.2006.00402.x"},{"key":"2021120905211791700_R4","doi-asserted-by":"crossref","unstructured":"Bachmann MT, Odermat B, Hengertner H, Zinkernagel RM. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med.\u20081996;183(5):2259\u20132269","DOI":"10.1084\/jem.183.5.2259"},{"key":"2021120905211791700_R5","doi-asserted-by":"crossref","unstructured":"Osmond DG. Population dynamics of bone marrow B lymphocytes. Immunol Rev.\u20081986;93:103\u2013124","DOI":"10.1111\/j.1600-065X.1986.tb01504.x"},{"key":"2021120905211791700_R6","doi-asserted-by":"crossref","unstructured":"Bernasconi N, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science.\u20082002;298(5601):2199\u20132202","DOI":"10.1126\/science.1076071"},{"key":"2021120905211791700_R7","doi-asserted-by":"crossref","unstructured":"Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine.\u20082003;21(suppl 2):S35\u2013S37","DOI":"10.1016\/S0264-410X(03)00198-1"},{"key":"2021120905211791700_R8","doi-asserted-by":"crossref","unstructured":"Andersson K, Wrammert J, Leanderson T. Affinity selection and repertoire shift: paradoxes as a consequence of somatic mutation?Immunol Rev.\u20081998;162:173\u2013182","DOI":"10.1111\/j.1600-065X.1998.tb01440.x"},{"key":"2021120905211791700_R9","doi-asserted-by":"crossref","unstructured":"McCool TL, Weiser JN. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun.\u20082004;72(10):5807\u20135813","DOI":"10.1128\/IAI.72.10.5807-5813.2004"},{"key":"2021120905211791700_R10","doi-asserted-by":"crossref","unstructured":"Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA.\u20082005;102(13):4848\u20134853","DOI":"10.1073\/pnas.0501254102"},{"key":"2021120905211791700_R11","doi-asserted-by":"crossref","unstructured":"Trzcinski K, Thompson CM, Srivastava A, Basset A, Malley R, Lipsitch M. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun.\u20082008;76(6):2678\u20132684","DOI":"10.1128\/IAI.00141-08"},{"key":"2021120905211791700_R12","doi-asserted-by":"crossref","unstructured":"Zhang Q, Bagrade L, Bernatoniene J, et al. Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children [published correction appears in J Infect Dis. 2008;197(9):1354]. J Infect Dis.\u20082007;195(8):1194\u20131202","DOI":"10.1086\/512617"},{"key":"2021120905211791700_R13","doi-asserted-by":"crossref","unstructured":"Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol.\u20082002;2(4):251\u2013262","DOI":"10.1038\/nri778"},{"key":"2021120905211791700_R14","doi-asserted-by":"crossref","unstructured":"Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M. Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int Immunol.\u20082008;20(9):1189\u20131199","DOI":"10.1093\/intimm\/dxn075"},{"key":"2021120905211791700_R15","doi-asserted-by":"crossref","unstructured":"Swain SL. Generation and in vivo persistence of polarized Th1 and Th2 memory cells. Immunity.\u20081994;1(7):543\u2013552","DOI":"10.1016\/1074-7613(94)90044-2"},{"key":"2021120905211791700_R16","doi-asserted-by":"crossref","unstructured":"Croft M, Swain SL. Analysis of CD4+ T cells that provide contact-dependent bystander help to B Cells. J Immunol.\u20081992;149(10):3157\u20133165","DOI":"10.4049\/jimmunol.149.10.3157"},{"key":"2021120905211791700_R17","doi-asserted-by":"crossref","unstructured":"Bachmann MF, Barner M, Viola, Kopf M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol.\u20081999;29(1):291\u2013299","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<291::AID-IMMU291>3.0.CO;2-K"},{"key":"2021120905211791700_R18","doi-asserted-by":"crossref","unstructured":"Viega-Fernandez H, Walter U, Bourgeois C, McLean A, Rocha B. Response of nai\u0308ve and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol.\u20082000;1(1):47\u201353","DOI":"10.1038\/76907"},{"key":"2021120905211791700_R19","doi-asserted-by":"crossref","unstructured":"Kaech SM, Ahmed R. Memory CD8+ cells differentiation: initial antigen encounter triggers a developmental program in nai\u0308ve cells. Nat Immunol.\u20082001;2(5):415\u2013422","DOI":"10.1038\/87720"},{"key":"2021120905211791700_R20","doi-asserted-by":"crossref","unstructured":"Bradley LM, Duncan DD, Tonkonogy SL, Swain SL. Characterization of antigen-specific CD4+ effector T cells in vivo: immunization results in a transient population of MEL\u221214\u2212, CD45RB-helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma. J Exp Med.\u20081991;174(3):547\u2013559","DOI":"10.1084\/jem.174.3.547"},{"key":"2021120905211791700_R21","doi-asserted-by":"crossref","unstructured":"Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol.\u20081990;145(11):3796\u20133806","DOI":"10.4049\/jimmunol.145.11.3796"},{"key":"2021120905211791700_R22","doi-asserted-by":"crossref","unstructured":"Azuma M, Cayabyab M, Phillips JH, Lanier LL. Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol.\u20081993;150(6):2091\u20132101","DOI":"10.4049\/jimmunol.150.6.2091"},{"key":"2021120905211791700_R23","doi-asserted-by":"crossref","unstructured":"Bradley LM, Duncan DD, Yoshimoto K, Swain SL. Memory effectors: a potent, IL-4 secreting helper T cell population that develops after restimulation with antigen. J Immunol.\u20081993;150(8 pt 1):3119\u20133130","DOI":"10.4049\/jimmunol.150.8.3119"},{"key":"2021120905211791700_R24","doi-asserted-by":"crossref","unstructured":"Gray D, Matzinger P. T cell memory is short-lived in the absence of antigen. J Exp Med.\u20081991;174(5):969\u2013974","DOI":"10.1084\/jem.174.5.969"},{"key":"2021120905211791700_R25","doi-asserted-by":"crossref","unstructured":"Oehen S, Waldner H, Kundig TM, Hengartner H, Zinkernagel RM. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J Exp Med.\u20081992;176(5):1273\u20131281","DOI":"10.1084\/jem.176.5.1273"},{"key":"2021120905211791700_R26","doi-asserted-by":"crossref","unstructured":"Lau LL, Jamieson BD, Somasundaram T, Ahmed R. Cytotoxic T cell memory without antigens. Nature.\u20081994;369(6482):648\u2013652","DOI":"10.1038\/369648a0"},{"key":"2021120905211791700_R27","doi-asserted-by":"crossref","unstructured":"Swain SL, Croft MC, Dubey C, et al. From naive to memory T cells. Immunol Rev.\u20081996;150:143\u2013167","DOI":"10.1111\/j.1600-065X.1996.tb00700.x"},{"key":"2021120905211791700_R28","doi-asserted-by":"crossref","unstructured":"Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell.\u20082006;124(4):783\u2013801","DOI":"10.1016\/j.cell.2006.02.015"},{"key":"2021120905211791700_R29","doi-asserted-by":"crossref","unstructured":"Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med.\u20082000;343(5):338\u2013344","DOI":"10.1056\/NEJM200008033430506"},{"key":"2021120905211791700_R30","doi-asserted-by":"crossref","unstructured":"Ulevitch RJ. Regulation of receptor-dependent activation of the innate immune response. J Infect Dis.\u20082003;187(suppl 2):S351\u2013S355","DOI":"10.1086\/374605"},{"key":"2021120905211791700_R31","doi-asserted-by":"crossref","unstructured":"Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev.\u20082004;199:227\u2013250","DOI":"10.1111\/j.0105-2896.2004.00144.x"},{"key":"2021120905211791700_R32","doi-asserted-by":"crossref","unstructured":"Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature.\u20082004;430(6996):257\u2013263","DOI":"10.1038\/nature02761"},{"key":"2021120905211791700_R33","doi-asserted-by":"crossref","unstructured":"Netea MG, Vand der Meer JWN, Sutmuller RP, Adema GJ, Kullberf B. From the Th1\/Th2 paradigm towards a Toll-like receptor\/T-helper bias. Antimicrob Agents Chemother.\u20082005;49(10):3991\u20133996","DOI":"10.1128\/AAC.49.10.3991-3996.2005"},{"key":"2021120905211791700_R34","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Voloshin T, Passador S. Kinetics of booster responses to Haemophilus influenzae type b conjugate after combined diphtheria-tetanus-acellular pertussis Haemophilus influenzae type b vaccination in infants. Pediatr Infect Dis J.\u20081999;18(12):1106\u20131108","DOI":"10.1097\/00006454-199912000-00019"},{"key":"2021120905211791700_R35","doi-asserted-by":"crossref","unstructured":"Madore DV, Johnson-Kraines CL, Rothstein EP, Smith DH. Kinetics of antibody response to Haemophilus influenzae type B vaccines. Curr Med Res Opin.\u20081999;15(2):105\u2013112","DOI":"10.1185\/03007999909113370"},{"key":"2021120905211791700_R36","doi-asserted-by":"crossref","unstructured":"Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis.\u20082006;43(11):1387\u20131394","DOI":"10.1086\/508776"},{"key":"2021120905211791700_R37","doi-asserted-by":"crossref","unstructured":"Tsai TF, Borrow R, Gnehm E, et al. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?Clin Vaccine Immunol.\u20082006;13(8):854\u2013861","DOI":"10.1128\/CVI.00059-06"},{"key":"2021120905211791700_R38","doi-asserted-by":"crossref","unstructured":"Anderson P, Ingram DL, Pichichero ME, Peter G. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis J.\u20082000;19(7):589\u2013591","DOI":"10.1097\/00006454-200007000-00001"},{"key":"2021120905211791700_R39","doi-asserted-by":"crossref","unstructured":"Eskola J, Olander R, Hovi T, Litmanen L, Peltola S, Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet.\u20081996;348(9043):1688\u20131692","DOI":"10.1016\/S0140-6736(96)04356-5"},{"key":"2021120905211791700_R40","doi-asserted-by":"crossref","unstructured":"Rennels MB, Englund J, Bernstein D, et al. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis\/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr Infect Dis J.\u20082000;19(5):417\u2013422","DOI":"10.1097\/00006454-200005000-00006"},{"key":"2021120905211791700_R41","doi-asserted-by":"crossref","unstructured":"McVernon J, Johnson PD, Pollard AJ, Slack MP, Moxon ER. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child.\u20082003;88(5):379\u2013383","DOI":"10.1136\/adc.88.5.379"},{"key":"2021120905211791700_R42","doi-asserted-by":"crossref","unstructured":"Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis.\u20082008;197(9):1275\u20131281","DOI":"10.1086\/586716"},{"key":"2021120905211791700_R43","doi-asserted-by":"crossref","unstructured":"Yeh CL, Kelly D, Ly-Mee Y, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis.\u20082008;46(2):186\u2013192","DOI":"10.1086\/524668"},{"key":"2021120905211791700_R44","doi-asserted-by":"crossref","unstructured":"Trotter CL, Andrews NJ, Kaczmarski B, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet.\u20082004;364(9431):365\u2013367","DOI":"10.1016\/S0140-6736(04)16725-1"},{"key":"2021120905211791700_R45","doi-asserted-by":"crossref","unstructured":"MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA.\u20082000;283(21):2795\u20132801","DOI":"10.1001\/jama.283.21.2795"},{"key":"2021120905211791700_R46","doi-asserted-by":"crossref","unstructured":"Snape M, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J.\u20082005;24(2):128\u2013131","DOI":"10.1097\/01.inf.0000151029.58752.27"},{"key":"2021120905211791700_R47","doi-asserted-by":"crossref","unstructured":"Schneerson R, Robbins J. Induction of serum Haemophilus influenzae type b capsular antibodies in adult volunteers fed cross reacting Escherichia coli. N Engl J Med.\u20081975;292(21):1093\u20131096","DOI":"10.1056\/NEJM197505222922103"},{"key":"2021120905211791700_R48","doi-asserted-by":"crossref","unstructured":"Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis b virus vaccination in Taiwan. J Infect Dis.\u20082003;187(1):134\u2013138","DOI":"10.1086\/345871"},{"key":"2021120905211791700_R49","doi-asserted-by":"crossref","unstructured":"Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15\u201318 years after neonatal immunization. J Infect Dis.\u20082008;197(10):1419\u20131425","DOI":"10.1086\/587695"},{"key":"2021120905211791700_R50","doi-asserted-by":"crossref","unstructured":"Stevens RH, Saxon A. Differential synthesis of IgM and IgG anti-tetanus toxoid antibody in vitro following in vivo booster immunization of humans. Cell Immunol.\u20081979;45(1):142\u2013150","DOI":"10.1016\/0008-8749(79)90369-1"},{"key":"2021120905211791700_R51","doi-asserted-by":"crossref","unstructured":"Vitek CR, Brennan MB, Gotway CA, et al. Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination. Lancet.\u20081999;353(9150):355\u2013358","DOI":"10.1016\/S0140-6736(98)03488-6"},{"key":"2021120905211791700_R52","doi-asserted-by":"crossref","unstructured":"Gergen P, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med.\u20081995;332(12):761\u2013766","DOI":"10.1056\/NEJM199503233321201"},{"key":"2021120905211791700_R53","doi-asserted-by":"crossref","unstructured":"Heininger U. Recent progress in clinical and basic pertussis research. Eur J Pediatr.\u20082001;160(4):203\u2013213","DOI":"10.1007\/PL00008429"},{"key":"2021120905211791700_R54","doi-asserted-by":"crossref","unstructured":"Jansen DL, Gray GC, Putnam SD, Lynn F, Meade BD. Evaluation of pertussis in U.S. Marine Corps trainees. Clin Infect Dis.\u20081997;25(5):1099\u20131107","DOI":"10.1086\/516099"},{"key":"2021120905211791700_R55","doi-asserted-by":"crossref","unstructured":"Cattaneo LA, Reed GW, Haase DH, Wills MJ, Edwards KM. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1\u201365 years. J Infect Dis.\u20081996;173(5):1256\u20131259","DOI":"10.1093\/infdis\/173.5.1256"},{"key":"2021120905211791700_R56","doi-asserted-by":"crossref","unstructured":"Esposito S, Agliardi T, Giammanco A, et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun.\u20082001;69(7):4516\u20134520","DOI":"10.1128\/IAI.69.7.4516-4520.2001"},{"key":"2021120905211791700_R57","doi-asserted-by":"crossref","unstructured":"Mancuso JD, Snyder A, Stigers J, et al. Pertussis outbreak in a US military community: Kaiserslauten, Germany, April\u2013June 2005. Clin Infect Dis.\u20082007;45(11):1476\u20131478","DOI":"10.1086\/522999"},{"key":"2021120905211791700_R58","doi-asserted-by":"crossref","unstructured":"Gilberg S, Njamkepo E, Parent du Chatelet I, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis.\u20082002;186(3):415\u2013418","DOI":"10.1086\/341511"},{"key":"2021120905211791700_R59","doi-asserted-by":"crossref","unstructured":"Schmitt-Grohe\u0301 S, Cherry JD, Heininger U, et al. Pertussis in German adults. Clin Infect Dis.\u20081995;21(4):860\u2013866","DOI":"10.1093\/clinids\/21.4.860"},{"key":"2021120905211791700_R60","unstructured":"Bin C, Zhihui C, Qichang L, et al. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull World Health Organ.\u20081991;69(4):415\u2013423"},{"key":"2021120905211791700_R61","doi-asserted-by":"crossref","unstructured":"Stittelaar K, De Swart RL, Osterhaus A. Vaccination against measles: a neverending story. Expert Rev Vaccines.\u20082002;1(2):151\u2013159","DOI":"10.1586\/14760584.1.2.151"},{"key":"2021120905211791700_R62","doi-asserted-by":"crossref","unstructured":"Cohen C, White JM, Savage EJ, et al. Vaccine effectiveness estimates, 2004\u20132005 mumps outbreak, England. Emerg Infect Dis.\u20082007;13(1):12\u201317","DOI":"10.3201\/eid1301.060649"},{"key":"2021120905211791700_R63","doi-asserted-by":"crossref","unstructured":"Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics.\u20081985;75(4):667\u2013671","DOI":"10.1542\/peds.75.4.667"},{"key":"2021120905211791700_R64","doi-asserted-by":"crossref","unstructured":"Anderson LJ, Seward JF. Mumps epidemiology and immunity: the anatomy of a modern epidemic. Pediatr Infect Dis J.\u20082008;27(10 suppl):S75\u2013S79","DOI":"10.1097\/INF.0b013e3181684d8d"},{"key":"2021120905211791700_R65","doi-asserted-by":"crossref","unstructured":"Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?Pediatrics.\u20082006;117(6). Available at: www.pediatrics.org\/cgi\/content\/full\/117\/6\/e1070","DOI":"10.1542\/peds.2005-2085"},{"key":"2021120905211791700_R66","doi-asserted-by":"crossref","unstructured":"Arvin A, Gershon A. Control of varicella: why is a two-dose schedule necessary?Pediatr Infect Dis J.\u20082006;25:475\u2013476","DOI":"10.1097\/01.inf.0000219484.55858.a2"},{"key":"2021120905211791700_R67","doi-asserted-by":"crossref","unstructured":"Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J.\u20081997;16(3):312\u2013322","DOI":"10.1097\/00006454-199703000-00011"},{"key":"2021120905211791700_R68","doi-asserted-by":"crossref","unstructured":"Glass RI, Parashar UD, Bresee JS, et al. Rotavirus vaccines: current prospects and future challenges. Lancet.\u20082006;368(9532):323\u2013332","DOI":"10.1016\/S0140-6736(06)68815-6"},{"key":"2021120905211791700_R69","doi-asserted-by":"crossref","unstructured":"Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology.\u20082001;279(1):361\u2013369","DOI":"10.1006\/viro.2000.0702"},{"key":"2021120905211791700_R70","doi-asserted-by":"crossref","unstructured":"Roden RB, Kirnbauer, Booy FP, Jessie J, Lowy DR, Schiller JT. In vitro generation and type-specific neutralization of a human papillomaviruses with the cell surface. J Virol.\u20081996;70(9):5875\u20135883","DOI":"10.1128\/jvi.70.9.5875-5883.1996"},{"key":"2021120905211791700_R71","doi-asserted-by":"crossref","unstructured":"Wang Z, Christensen N, Schiller JT, Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol.\u20081997;78(pt 9):2209\u20132215","DOI":"10.1099\/0022-1317-78-9-2209"},{"key":"2021120905211791700_R72","doi-asserted-by":"crossref","unstructured":"Day PM, Gambhira R, Roden RBS, Lowy DR, Schiler JT. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol.\u20082008;82(9):4638\u20134646","DOI":"10.1128\/JVI.00143-08"},{"key":"2021120905211791700_R73","doi-asserted-by":"crossref","unstructured":"Zhou J, Gissman L, Zentgraf H, Muller H, Picken M, Muller M. Early phase in the infection of cultured cells with papillomavirus virions. Virology.\u20081995;214(1):167\u2013176","DOI":"10.1006\/viro.1995.9943"},{"key":"2021120905211791700_R74","doi-asserted-by":"crossref","unstructured":"Liu WJ, Wi YM, Shao, KN, Liu YH, Liu XS, Frazer IH. Association of bovine papillomavirus type 1 with microtubules. Virology.\u20082001;282(2):237\u2013244","DOI":"10.1006\/viro.2000.0728"},{"key":"2021120905211791700_R75","doi-asserted-by":"crossref","unstructured":"Sibbet G, Romero-Graillet C, Meneguzzi G, Campo MS. \u03b1 6 integrin is not the obligatory cell receptor for bovine papillomavirus type 4 [published correction appears in J Gen Virol. 2000;81(pt 6):1629]. J Gen Virol.\u20082000;81(pt 2):327\u2013334","DOI":"10.1099\/0022-1317-81-2-327"},{"key":"2021120905211791700_R76","doi-asserted-by":"crossref","unstructured":"Ozbun MA. Infectious human papillomavirus type 31b: purification and infection of an immortalized human keratinocyte cell line. J Gen Virol.\u20082002;83(pt 11):2753\u20132763","DOI":"10.1099\/0022-1317-83-11-2753"},{"key":"2021120905211791700_R77","doi-asserted-by":"crossref","unstructured":"Culp TD, Christensen ND. Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology.\u20082004;319(1):152\u2013161","DOI":"10.1016\/j.virol.2003.11.004"},{"key":"2021120905211791700_R78","doi-asserted-by":"crossref","unstructured":"Stanley M. Immune responses to human papillomavirus. Vaccine.\u20082006;24:(suppl 1):S16\u2013S22","DOI":"10.1016\/j.vaccine.2005.09.002"},{"key":"2021120905211791700_R79","doi-asserted-by":"crossref","unstructured":"Carter JJ, Koutsky LA, Hughers JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis.\u20082000;181(6):1911\u20131919","DOI":"10.1086\/315498"},{"key":"2021120905211791700_R80","doi-asserted-by":"crossref","unstructured":"Ho GYF, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev.\u20082004;13(1):110\u2013116","DOI":"10.1158\/1055-9965.EPI-03-0191"},{"key":"2021120905211791700_R81","doi-asserted-by":"crossref","unstructured":"Prakash S, Patterson S, Kapembwa MS. Macrophages are increased in cervical epithelium of women with cervicitis. Sex Transm Infect.\u20082001;77(5):366\u2013369","DOI":"10.1136\/sti.77.5.366"},{"key":"2021120905211791700_R82","doi-asserted-by":"crossref","unstructured":"Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet.\u20082004;364(9447):1757\u20131765","DOI":"10.1016\/S0140-6736(04)17398-4"},{"key":"2021120905211791700_R83","doi-asserted-by":"crossref","unstructured":"Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer.\u20082006;95(11):1459\u20131466","DOI":"10.1038\/sj.bjc.6603469"},{"key":"2021120905211791700_R84","doi-asserted-by":"crossref","unstructured":"Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine.\u20082006;24(suppl 3):S106\u2013S113","DOI":"10.1016\/j.vaccine.2006.05.110"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/6\/1633\/1022303\/zpe01209001633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/6\/1633\/1022303\/zpe01209001633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T17:05:56Z","timestamp":1685207156000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/124\/6\/1633\/72192\/Booster-Vaccinations-Can-Immunologic-Memory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,1]]},"references-count":84,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,12,1]]},"published-print":{"date-parts":[[2009,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-3645","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,1]]}}}